Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.
Spinal muscular atrophy (SMA) is one of the most common neuromuscular autosomal recessive disorders. The incidence is about 1:10,000 livebirths. There are 5 subgroups base on onset of symptoms and clinical severity. Type 1 is the most severe type which age of onset is 6 months old and life expectancy is less than 1-2 years. SMA carrier frequency is approximately 1/40-1/60. Molecular genetic testing to detect copies number of SMN1 gene is possible with as high as 95% detection rate. Since 2008, American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG) recommended SMA preconceptional and prenatal carrier screening in general population. In Thailand, there are no standard protocol for SMA prenatal carrier screening.
Study Type
OBSERVATIONAL
Enrollment
200
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Ratchathewi, Bangkok, Thailand
RECRUITINGRate of acceptance of prenatal carrier screening for spinal muscular atrophy
Rate of acceptance of prenatal carrier screening for spinal muscular atrophy among pregnant women seeking prenatal care
Time frame: 12 months
Factors associated rate of acceptance of prenatal carrier screening for spinal muscular atrophy
Factors associated rate of acceptance of prenatal carrier screening for spinal muscular among pregnant women seeking prenatal care
Time frame: 12 months
Copies number of SMN1 and SMN2 genes in pregnant women
Copies number of SMN1 and SMN2 genes in pregnant women among individuals who accepted carrier screening
Time frame: 12 months
Carrier frequency among individuals who accepted carrier screening
Screen positive rate or rate of having 1 copy of SMN1 among individuals who accepted carrier screening
Time frame: 12 months
Pregnant women's attitudes toward spinal muscular atrophy and carrier screening
After genetic counseling, pregnant women's attitudes toward spinal muscular atrophy and carrier screening will be evaluated by validated questionnaire.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.